Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
The first drug ever approved for OSA — and the indication that can unlock coverage weight loss alone cannot.
Obstructive sleep apnea had no approved drug treatment. The options were CPAP, oral appliances, surgery and weight loss — nothing you could take. That changed when the FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity, the first and only prescription medication for the condition.
The trial results are not marginal. In the SURMOUNT-OSA program, adults taking Zepbound experienced a 58.7% reduction in the apnea-hypopnea index against a 2.5% reduction on placebo. Lilly reported a mean AHI reduction of up to 63% — roughly 30 fewer breathing events per hour.
There is also a practical consequence most coverage misses. The American Academy of Sleep Medicine notes that some Medicare plans with drug coverage may cover Zepbound for treating OSA but not for weight loss alone. For patients who have been denied coverage for obesity, an OSA diagnosis can change the answer entirely.
Zepbound (tirzepatide) is approved for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Note both halves of that: it is not approved for OSA in people without obesity, and it is not approved for mild OSA. It works largely by reducing weight, which reduces the airway obstruction driving the apnea.
Two phase 3 trials — one in patients not using CPAP, one in patients using it. Baseline severity was high in both.
| Measure | Result |
|---|---|
| Baseline mean AHI | 51.5 events per hour (trial 1); 49.5 events per hour (trial 2) |
| AHI reduction on Zepbound | 58.7% from baseline |
| AHI reduction on placebo | 2.5% from baseline |
| Mean AHI reduction reported by Lilly | Up to 63%, about 30 fewer events per hour |
| Absolute improvement | Roughly 25 to 29 fewer events per hour across the trials |
| Accompanying weight loss | Roughly 18% to 20% of body weight |
| Other outcomes at 1 year | Significant reductions in OSA-related nocturnal hypoxia and OSA severity vs placebo |
An AHI of 5-15 events per hour is generally considered mild OSA, 15-30 moderate, and above 30 severe. Participants started deep into the severe range.
This is the most practically useful thing on this page. Many insurance plans, including Medicare, exclude medications used solely for weight loss. That exclusion has kept GLP-1s out of reach for a lot of people who clinically qualify.
An approved indication for a different condition changes the coverage question. The American Academy of Sleep Medicine has noted that some Medicare plans with drug coverage may cover Zepbound for treating OSA but not for weight loss alone — because OSA is a disease being treated, not weight management.
The same logic applies to the other non-weight-loss indications in this drug class. Wegovy carries an approved indication to reduce major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease. Ozempic is approved to reduce the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease.
If you have been denied coverage for weight management, it is worth asking your clinician whether you have an undiagnosed condition with its own indication. Sleep apnea in particular is substantially underdiagnosed, and a sleep study is a reasonable thing to request if you have the symptoms.
OSA is common in people with obesity and frequently undiagnosed. These are the symptoms clinicians typically screen on — this is not a diagnostic tool, and only a sleep study can establish OSA.
Diagnosis requires a sleep study, either in a lab or via an approved home test. Ask your primary care clinician for a referral if these apply to you.
Not straightforwardly, and anyone telling you otherwise is overselling it. The SURMOUNT-OSA program included both patients using CPAP and patients not using it, and tirzepatide showed benefit in both — but a 58.7% reduction in AHI from a baseline around 50 events per hour still leaves meaningful residual apnea for many patients.
For someone with severe OSA who cannot tolerate CPAP, a large reduction in AHI is clinically valuable even if it does not normalise their sleep. For someone doing well on CPAP, this is a conversation about whether adding tirzepatide might eventually reduce their reliance on it.
Either way, this is a decision for a sleep physician with your actual sleep study data, not something to self-direct. Stopping CPAP because you have started a GLP-1 is not a safe assumption.
Zepbound pricing is the same product regardless of which indication it was prescribed for, so the routes covered in our cost guide all apply. Through LillyDirect, self-pay pricing runs $299 a month for 2.5 mg, $399 for 5 mg and $449 for higher doses, against a list price of $499 to $1,086 per fill. Walmart pharmacies offer retail pick-up at LillyDirect pricing from $349 a month.
The difference the OSA indication makes is on the insurance side. If your plan covers Zepbound for OSA but excludes weight-management medication, that changes your cost from several hundred dollars a month to a copay.
For Medicare specifically, note that the GLP-1 Bridge program covering certain GLP-1s at $50 a month runs July 1, 2026 through December 31, 2027 and includes the Zepbound KwikPen — but only the KwikPen formulation, not the vials.
Yes. The FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first and only prescription medication approved for OSA. It is not approved for mild OSA or for OSA in people without obesity.
In the SURMOUNT-OSA trials, adults taking Zepbound experienced a 58.7% reduction in the apnea-hypopnea index against a 2.5% reduction on placebo. Lilly reported a mean AHI reduction of up to 63%, about 30 fewer breathing events per hour, alongside roughly 18% to 20% weight loss. Participants started with a baseline mean AHI around 50 events per hour.
Not automatically, and this is a decision for a sleep physician rather than something to self-direct. A 58.7% AHI reduction from a baseline near 50 events per hour still leaves meaningful residual apnea for many patients. The trials included both CPAP users and non-users and showed benefit in both, but stopping CPAP because you have started a GLP-1 is not a safe assumption.
Sometimes, and this is genuinely important. The American Academy of Sleep Medicine has noted that some Medicare plans with drug coverage may cover Zepbound for treating OSA but not for weight loss alone, because OSA is a disease being treated rather than weight management. If you have been denied for weight loss, it is worth asking your clinician about a sleep study.
The apnea-hypopnea index counts breathing events — apneas and hypopneas — per hour of sleep. An AHI of 5 to 15 is generally considered mild OSA, 15 to 30 moderate, and above 30 severe. SURMOUNT-OSA participants had a baseline mean AHI around 50, placing them well into the severe range.
Wegovy is not FDA-approved for obstructive sleep apnea. Zepbound is the only GLP-1 medication with that indication. Wegovy does carry a separate approved indication to reduce major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease.
The same as for any indication. LillyDirect self-pay runs $299 a month for 2.5 mg, $399 for 5 mg and $449 for higher doses, with Walmart retail pick-up from $349. The OSA indication may change what your insurance pays rather than what the drug costs. Eligible Medicare beneficiaries can access the Zepbound KwikPen for $50 a month under the GLP-1 Bridge program.
Cardiovascular, kidney and other approved indications
Titration schedule
Using an indication to get covered
Zepbound KwikPen at $50/month
Manufacturer-direct Zepbound pricing
How the two compare
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete guide explaining the difference between semaglutide, Ozempic, Wegovy, and compounded semaglutide.
Complete guide to Jardiance weight loss: how much to expect, mechanism, and comparison to GLP-1 medications.
The SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% average weight loss, plus side effects and cost.
What actually differs, what the FDA changed in 2026, and how the price gap closed.
The oral GLP-1 pill approved April 1, 2026: dosing from 0.8 mg, pricing from $149/mo, and results.
The higher-dose semaglutide approved March 19, 2026, delivering 20.7% mean weight loss.
This article summarizes published clinical trial results and FDA approval information and is for informational purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Obstructive sleep apnea requires diagnosis by a qualified clinician, normally via a sleep study. Do not stop or reduce CPAP therapy based on this article — that decision belongs to your sleep physician. Zepbound is a prescription medicine with serious potential risks including boxed warnings and is not appropriate for everyone. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026